Trials / Conditions / Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

28 registered clinical trials studyying Progressive Supranuclear Palsy (PSP) — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies NCT07240805	BioSensics	—
Not Yet Recruiting	The Progressive Supranuclear Palsy Clinical Trial Platform NCT07173803	Adam Boxer	Phase 2
Recruiting	First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Ima NCT07348276	Invicro	EARLY_Phase 1
Not Yet Recruiting	Collection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker NCT07141719	University of Kiel	—
Recruiting	The CurePSP Genetics Program NCT06647641	Massachusetts General Hospital	—
Enrolling By Invitation	Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely NCT06597071	NeuraLight	N/A
Recruiting	AI-Enhanced Optimization of Acute Levodopa Challenge Test NCT06949865	Beijing Tiantan Hospital	—
Recruiting	Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844	Centre Hospitalier Universitaire de Liege	N/A
Active Not Recruiting	Neuroinflammation in FTLD NCT06870838	Leiden University Medical Center	—
Recruiting	Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Dig NCT07392411	Beijing Tiantan Hospital	—
Recruiting	Synaptic Loss in Multiple System Atrophy NCT05121012	University of Exeter	—
Completed	Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Pa NCT04539041	Novartis Pharmaceuticals	Phase 1
Completed	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission C NCT04193527	GE Healthcare	Phase 3
Recruiting	UPenn Observational Research Repository on Neurodegenerative Disease NCT04715399	University of Pennsylvania	—
Recruiting	ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) NCT04363684	Mayo Clinic	—
Completed	Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E1 NCT03413319	AbbVie	Phase 1
Terminated	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) NCT03391765	AbbVie	Phase 2
Completed	Human CNS Tau Kinetics in Tauopathies NCT03545126	Washington University School of Medicine	—
Completed	ADDIA Proof-of-Performance Clinical Study NCT03030586	Amoneta Diagnostics SAS	—
Completed	Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy NCT02839642	Assistance Publique Hopitaux De Marseille	Phase 3
Completed	4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 NCT02966145	University of California, San Francisco	—
Completed	Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients Wit NCT02531360	Molecular NeuroImaging	EARLY_Phase 1
Unknown	PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK NCT02778607	University College, London	—
Completed	Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) NCT02365922	University of California, San Francisco	—
Completed	Safety Study of TPI-287 to Treat CBS and PSP NCT02133846	University of California, San Francisco	Phase 1
Completed	Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy S NCT02103894	Molecular NeuroImaging	Phase 1
Completed	Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI) NCT01888185	Milton S. Hershey Medical Center	—